Maternal HIV-1 treatment protects against transmission to newborns
Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding. view more (2009-10-19)
Weighing costs, benefits of HIV treatments
Prevention versus treatment? Cost versus efficacy? So go two of the dilemmas looming over Dartmouth's Paul E. Palumbo, M.D., and his fellow researchers in the race to fight HIV and other infectious diseases in the developing world - especially among women and their young children. view more (2009-09-16)
Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV
Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report. view more (2009-01-06)
Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa
More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 because a feasible and timely antiretroviral (ARV) treatment program was not implemented, assert researchers from the Harvard School of Public Health (HSPH) in a study published online by the Journal of Acquired Immune Deficiency Syndromes (JAIDS)... view more... (2008-10-21)
Efavirenz-Based Initial Therapies Associated with Better Outcomes in HIV-Infected Adults
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. view more (2008-10-15)
Certain HIV treatment less effective when used with anti-TB therapy
Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy. view more (2008-08-04)
Findings offer insights into role of breastfeeding in preventing infant death, HIV infection
In many poor countries, mothers with HIV face a stark choice: to nurse their infants, and risk passing on HIV through their breast milk-or to formula feed, and deprive their infants of much of the natural immunity needed to protect against fatal diseases of early infancy. view more (2008-06-05)
Extended infant antiretroviral prophylaxis reduces HIV risk during breastfeeding
In many resource-poor countries, infants born to mothers with HIV receive a single dose of nevirapine (NVP) and a one-week dose of zidovudine (ZDV) to prevent transmission of HIV from the mother to her newborn. view more (2008-06-05)
Breastfeeding now safer for infants of HIV-infected mothers
An antiretroviral drug already in widespread use in the developing world to prevent the transmission of HIV from infected mothers to their newborns during childbirth has also been found to substantially cut the risk of subsequent HIV transmission during breast-feeding. view more (2008-02-05)
HIV drug resistance risk in mothers reduced by combination of common drugs
New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options. view more (2007-11-12)
Delay in use of nevirapine-based AIDS treatment can improve outcomes
Delaying the use of nevirapine-containing antiretroviral therapy (ART) for at least six months after labor may improve treatment outcomes among HIV-infected women in developing countries who took nevirapine during labor to prevent their babies from becoming infected, suggests a new study in The New England Journal of Medicine. view more (2007-01-11)
Response to anti-HIV therapy improved if treatment within 6 months after preventive regimen
A woman's response to HIV treatment with drug combinations that contain nevirapine is improved if at least six months have passed after she received the drug as a single dose during labor to prevent passing HIV on to her child. view more (2007-01-11)
Study finds limited options for backup HIV treatment in some developing countries
Thai researchers have discovered that patients who fail treatment with a commonly used, inexpensive, first-line antiretroviral therapy (ART) are also usually resistant to other, similar drugs, leaving progressively fewer options for replacement therapies. view more (2007-01-09)
Study finds limited options for backup HIV treatment in some developing countries
Thai researchers have discovered that patients who fail treatment with a commonly used, inexpensive, first-line antiretroviral therapy (ART) are also usually resistant to other, similar drugs, leaving progressively fewer options for replacement therapies. view more (2007-01-09)
Drug to Block Mother-to-Child HIV Transmission Induces Resistance
The incidence of drug resistance associated with single-dose nevirapine, a drug used to prevent mother-to-child transmission of HIV-1, may be substantially higher than previously thought and of particular risk for those infected with HIV-1 subtype C, according to three new studies published in the July 1 issue of The Journal of Infectious... view more... (2005-06-02)
Nevirapine a better HIV drug? Press Release for PLoS Medicine
Nevirapine is Better than Efavirenz at Raising "Good" Cholesterol Two of the most commonly prescribed drugs for treating HIV (antiretroviral drugs)-nevirapine and efavirenz-can both raise levels of the "good type" of cholesterol (HDL cholesterol), but nevirapine raises it higher than efavirenz, according to a new study by... view more... (2004-10-13)
Aids In Thailand: First Step Towards Eradication Of Mother To Child Transmission?
Aids is one of the principal causes of infant mortality in many developing countries. Viral transmission takes place during pregnancy (in utero), at the moment of childbirth or even during breastfeeding. If no treatment is given, the virus is transmitted to about 35% of children of infected mothers. The use of a preventive treatment with... view more... (2004-07-01)
Aids: A Single-Tablet Generic Tritherapy Tested Successfully In Cameroon
WHO's objective is to enable 3 million people living with HIV to have access to antiretroviral treatments by 2005. The development of simple and inexpensive generic fixed-dose combined therapies appears the most suitable solution for making possible this access to treatments in developing countries with meagre resources. The tritherapies that... view more... (2004-07-01)
Antiretroviral Therapy Effective In Reducing Mother-to-child HIV-1 Transmission When Started After Childbirth (p 1171)
Results of a study from Malawi in this week's issue of THE LANCET highlight how antiretroviral therapy targeted at babies soon after childbirth (because their mothers' HIV diagnosis was made around the time of delivery) is still effective in preventing vertical HIV-1 transmission from mothers to their children. Zidovudine and nevirapine have been... view more... (2003-10-08)
Further evidence for effectiveness of nevirapine in reducing mother-to-child HIV-1 transmission (pp 842, 859)
Issue 13 September 2003 Embargoed 0001 h (London time) 12 September 2003. A follow-up study among mothers with HIV-1 and their infants in this week's issue of THE LANCET provides further evidence for the sustained efficacy of nevirapine as a low-cost option to help prevent vertical HIV-1 transmission from mothers to newborn children in... view more... (2003-09-10)
|
|
